BioSpace News Archive

Business

Diabetes Technology Leader and Global Business Executive Doug Lawrence Joins Hygieia as CEO

Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav® Insulin Management Program.

August 23, 2022
·
4 min read
FDA

Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

Synlogic, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SYNB1353 for the potential treatment of homocystinuria (HCU).

August 23, 2022
·
6 min read
FDA

K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Advisory Board for Lead Program KTX-1001

K36 Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for the Company’s lead program KTX-1001.

August 23, 2022
·
4 min read
Genetown

BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China

BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China.

August 23, 2022
·
7 min read
Drug Development

Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS

Foghorn ® Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on the Phase 1 dose escalation study of FHD-286.

August 23, 2022
·
4 min read
Biotech Beach

Modified bladder cancer treatment shows promise in animal studies

A modified tuberculosis vaccine developed at Texas Biomedical Research Institute could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects.

August 23, 2022
·
3 min read
Business

Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer

Mythic Therapeutics announced today the appointment of Gilles Gallant, BPharm, PhD, FOPQ, to the new position of Chief Development Officer.

August 23, 2022
·
3 min read
Biotech Bay

Lucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Lucira Health, Inc. today announced that the company will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31st , 2022.

August 23, 2022
·
1 min read
Business

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

GH Research PLC today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business.

August 23, 2022
·
7 min read
Genetown

Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers

Aktis Oncology today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225.

August 23, 2022
·
2 min read